COVIRIX Medical

We are a team of professionals with complementary expertise and deep experience in healthcare, biotech, drug development, synthesis and testing, and investment banking. The company was incorporated in March 2020 with a mission to repurpose antiviral and anti-inflammatory drugs for treatment of COVID-19. Collectively our team has over 200 years of relevant industry experience.

We believe we can successfully repurpose pharmaceutical drugs, firstly with proven antiviral efficacy against the SARS-CoV-2 virus, secondly with adjunctive anti-inflammatory properties, and finally for delivery via oral inhalation and intranasal inhalation routes as highly targeted treatment options against the current pandemic.

Our team has demonstrated experience in the manufacture, formulation, synthesis and testing of pharmaceuticals. Crucially, we’re preparing for the future. Our capacity for research and development means that we can keep our sights above the horizon. We’re responding to COVID-19 but also ensuring that our practices are preparing us for future mutations of the virus as well as the inevitable next respiratory virus pandemic.


What we are aiming for at COVIRIX is an effective and proven inhaled therapy that can be safely and cheaply produced to be distributed on a universal non-discriminatory manner for treatment and prophylaxis with freedom of known short- or long-term side effects.

Our business plan includes the concomitant development of both an inhaled antiviral and a non-steroidal anti-inflammatory that we believe will also effectively combat the Long-COVID syndrome, and in addition, replace the stand-alone use of inhaled steroids for many inflammatory pulmonary conditions like asthma, COPD and ILD.

The medical, social and economic distress caused by the pandemic demand a quick and effective response that is only possible by clear communication and intentional collaboration. COVIRIX is seeking active collaborative engagement with health authorities to expedite the delivery and impact of its antiviral solutions.